Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216029 · ClinicalTrials.gov registry record · NA
Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma
A NA study of Sarcoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT05216029: Active NA study of Sarcoma, sponsored by M.D. Anderson Cancer Center.
NCT05216029 is a NA study of Sarcoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 92 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216029, a NA study of Sarcoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial investigates whether measuring and presenting information about a patient's cancer treatment to them, their doctor, and their radiologist using a tool called an "oncology dashboard" may help patients understand the disease better and help the patient's medical team manage their care more efficiently. The oncology dashboard tool may help patients understand the disease better and may help improve the efficiency of their medical care.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Informational Intervention
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2027-02-02 |
| Phase | NA |
What the registry record for NCT05216029 still lists
NCT05216029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT05216029 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05216029 about?
NCT05216029 is a clinical study titled "Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma". This clinical trial investigates whether measuring and presenting information about a patient's cancer treatment to them, their doctor, and their radiologist using a tool called an "oncology dashboard" may help patients understand the disease better and help the patient's medical team manage their c...
What is the current status of trial NCT05216029?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 92 participants. The study started on 2015-10-01. Estimated completion is 2027-02-02.
What conditions does trial NCT05216029 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT05216029?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Informational Intervention (OTHER).
Who is sponsoring clinical trial NCT05216029?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05216029 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05216029's enrollment target sits among peer trials
92 45th of 122 higher than 78 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
-
Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients
RECRUITING · NA
-
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
RECRUITING · NA
-
Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
RECRUITING · NA
-
GRID Therapy for Extremity Soft Tissue Sarcoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy